Beranda › Neuroblastoma
Uji klinis Neuroblastoma yang merekrut di AS
47 studi untuk Neuroblastoma merekrut peserta di lokasi di seluruh Amerika Serikat.
Kota dengan studi terbanyak
- Boston, MA13 studi
- Washington, DC11 studi
- New York City, NY10 studi
- Philadelphia, PA9 studi
- Dallas, TX9 studi
- Memphis, TN9 studi
- St. Louis, MO9 studi
- Hartford, CT8 studi
- Aurora, CO8 studi
- Birmingham, AL8 studi
- Minneapolis, MN8 studi
- Atlanta, GA7 studi
- San Francisco, CA7 studi
- Los Angeles, CA7 studi
- Cincinnati, OH7 studi
- Miami, FL7 studi
- Orlando, FL7 studi
- Houston, TX7 studi
- Seattle, WA6 studi
- Gainesville, FL6 studi
- Chicago, IL6 studi
- Harrisburg, PA6 studi
- Honolulu, HI6 studi
- Little Rock, AR6 studi
- Durham, NC6 studi
- Greenburgh, NY6 studi
- Portland, OR6 studi
- Salt Lake City, UT6 studi
- Columbus, OH5 studi
- Ann Arbor, MI5 studi
- Nashville, TN5 studi
- Mountain View, CA5 studi
- Austin, TX5 studi
- Oakland, CA5 studi
- San Diego, CA5 studi
- Fort Worth, TX4 studi
- Clifton, NJ4 studi
- Edison, NJ4 studi
- Louisville, KY4 studi
- Charleston, SC4 studi
Berdasarkan negara bagian
- Alabama8 studi
- Arizona3 studi
- Arkansas6 studi
- California14 studi
- Colorado8 studi
- Connecticut9 studi
- Distrik Columbia6 studi
- Florida9 studi
- Georgia9 studi
- Hawaii6 studi
- Illinois6 studi
- Indiana3 studi
- Iowa3 studi
- Kentucky5 studi
- Maryland8 studi
- Massachusetts13 studi
- Michigan8 studi
- Minnesota9 studi
- Missouri10 studi
- New Jersey6 studi
- New York13 studi
- North Carolina7 studi
- North Dakota3 studi
- Ohio8 studi
- Oregon6 studi
- Pennsylvania14 studi
- Rhode Island3 studi
- South Carolina4 studi
- South Dakota3 studi
- Tennessee12 studi
- Texas15 studi
- Utah6 studi
- Virginia3 studi
- Washington6 studi
- Wisconsin4 studi
Studi yang baru diperbarui
Teks studi resmi (Bahasa Inggris)
MCT for the Harvard/UCSF ROBIN Center
Menerima peserta
Semua usia · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06000787A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma
Menerima pesertaFase 2Sukarelawan sehat diterima
Semua usia · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT04936529Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies
Menerima pesertaStudi observasionalSukarelawan sehat diterima
4 Weeks · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT01109394Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
Menerima pesertaFase 3
Hingga usia 30 · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT06172296Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma
Menerima pesertaFase 1
Usia 3 hingga 35 · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT06995872Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms
Menerima pesertaStudi observasional
Usia 4 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT01005654Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Menerima pesertaFase 1/2
6 Months – 25 Years · Semua jenis kelamin · Diperbarui 17 Sep 2026 · NCT06395103Biomarkers of Resiliency In Childhood Cancer Surgery
Menerima pesertaStudi observasional
Usia 3 hingga 25 · Semua jenis kelamin · Diperbarui 14 Sep 2026 · NCT06674811Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
Menerima pesertaFase 2
Hingga usia 22 · Semua jenis kelamin · Diperbarui 4 Sep 2026 · NCT02559778Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
Menerima pesertaFase 1/2
Hingga usia 26 · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT06465199International Congenital Central Hypoventilation Syndrome (CCHS) Registry and CCHS SHARE
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT03088020Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
Menerima pesertaFase 2
Usia 1 hingga 21 · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT06540963B7-H3.CD28Z.CART in Solid Tumors
Menerima pesertaFase 1
9 Months – 30 Years · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT07358260Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
Menerima pesertaFase 1/2
Hingga usia 30 · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT06541262N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma
Menerima pesertaFase 2
18 Months – 19 Years · Semua jenis kelamin · Diperbarui 28 Agu 2026 · NCT06528496Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Menerima pesertaFase 3
365 Days – 30 Years · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT03126916Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Menerima pesertaFase 1/2
12 Months – 30 Years · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT04851119Haploidentical Donor Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Neuroblastoma
Menerima pesertaFase 2
Usia 1 hingga 39 · Semua jenis kelamin · Diperbarui 24 Agu 2026 · NCT07635056Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)
Menerima pesertaFase 1
Usia 1 hingga 23 · Semua jenis kelamin · Diperbarui 13 Agu 2026 · NCT07172958Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
Menerima pesertaFase 2
12 Months – 21 Years · Semua jenis kelamin · Diperbarui 12 Agu 2026 · NCT05489887SPEARHEAD-3 Pediatric Study
Menerima pesertaFase 1/2
Usia 2 hingga 21 · Semua jenis kelamin · Diperbarui 11 Agu 2026 · NCT05642455A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma
Menerima pesertaFase 2
Semua usia · Semua jenis kelamin · Diperbarui 28 Jul 2026 · NCT06057948PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Menerima pesertaFase 1/2
Usia 1 hingga 30 · Semua jenis kelamin · Diperbarui 22 Jul 2026 · NCT06721689NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma
Menerima pesertaFase 1
Usia 1 hingga 24 · Semua jenis kelamin · Diperbarui 21 Jul 2026 · NCT07211737NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
Menerima pesertaFase 2
Usia 1 hingga 31 · Semua jenis kelamin · Diperbarui 20 Jul 2026 · NCT06450041Dari ClinicalTrials.gov, data diambil 2 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.